Multiple Myeloma - Antibody Drug Conjugates Market Statistics
The global multiple myeloma antibody drug conjugates market size was valued at US$ 126.4 million in 2021 and is estimated to grow at a compound annual growth rate (CAGR) of 28.7% from 2021 to 2030.
Related Statistics
Multiple Myeloma - Antibody drug conjugates market highlights
- The global multiple myeloma segment generated a revenue of USD 126.4 million in 2021 and is expected to reach USD 1,220.3 million by 2030.
- The market is expected to grow at a CAGR (2022 - 2030) of 20.6% by 2030.
- In terms of region, North America was the largest revenue generating market in 2021.
- Country-wise, China is expected to register the highest CAGR from 2022 to 2030.
Market summary
| Market revenue in 2021 | USD 126.4 million |
| Market revenue in 2030 | USD 1,220.3 million |
| Growth rate | 20.6% (CAGR from 2022 to 2030) |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody drug conjugates market segmentation & scope
Antibody Drug Conjugates Market Outlook
- HTML
- PPT
- -
Everything on Antibody Drug Conjugates Market in one document: edited and divided into chapters, including detailed references.
Related industry reports
Related Regional Reports
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
